Acurx Pharmaceuticals, Inc. (ACXP)
SEC filings, financial facts, source resources, and Goglides workspace context for Acurx Pharmaceuticals, Inc..
OpenSearch uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for Acurx Pharmaceuticals, Inc..
OpenClear Secure reported FY2025 revenue of $900.8 million and Q1 2026 revenue of $253.0 million, with the official record tying the thesis to airport-member growth, identity platform expansion, deferred revenue, privacy trust, margin quality and cash conversion.
OpenAcurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution become
Open